Prevalence and duration of anti-SARS-CoV-2 antibodies in healthcare workers

被引：0

作者：

Johannesen, Caroline Klint ^{[1
]}

St Martin, Gry ^{[2
]}

Lendorf, Maria Elisabeth ^{[1
]}

Gerred, Peter ^{[3
,4
]}

Fyfe, Alexander ^{[5
]}

Paton, Robert S. ^{[5
]}

Thompson, Craig ^{[5
]}

Molsted, Stig ^{[1
]}

Kann, Caroline Elisabeth ^{[2
]}

Jensen, Claus Antonio ^{[1
]}

Hansen, Cecilie Bo ^{[3
]}

Lokkegaard, Ellen ^{[1
,4
]}

Christensen, Thomas Broe ^{[1
]}

Simons, Peter ^{[6
]}

Fischer, Thea K. ^{[1
,4
]}

机构：

[1] Copenhagen Univ Hosp, Nordsjaellands Hosp, Copenhagen, Denmark

[2] Nykobing F Hosp, Nykobing, Denmark

[3] Copenhagen Univ Hosp, Dept Clin Immunol, Sect 7631, Lab Mol Med,Rigshosp, Copenhagen, Denmark

[4] Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark

[5] Univ Oxford, Dept Zool, Oxford, England

[6] Univ Oxford, Nuffield Dept Med, Oxford, England

来源：

DANISH MEDICAL JOURNAL | 2022年 / 69卷 / 05期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Introduction. Knowledge of the seroprevalence and duration of antibodies against SARS-CoV-2 was needed in the early phases of the COVID-19 pandemic and is still necessary for policy makers and healthcare professionals. This information allows us to better understand the risk of reinfection in previously infected individuals. Methods. We investigated the prevalence and duration of detectable antibodies against SARS-CoV-2 in sequentially collected samples from 379 healthcare professionals. Results. SARS-CoV-2 seroprevalence at inclusion was 5.3% (95% confidence interval (CI): 3.3-8.0%) and 25% of seropositive participants reverted during follow-up. At the end of follow-up, the calculated probability of having detectable antibodies among former seropositive participants was 72.2% (95% CI: 54.2-96.2%). Conclusion. Antibodies against SARS-CoV-2 were detectable in a subset of infected individuals for a minimum of 39 weeks.

引用

页数：9

共 50 条

[1] High seroprevalence of anti-SARS-CoV-2 antibodies among Ethiopian healthcare workers
Gelanew, Tesfaye
Seyoum, Berhanu
Mulu, Andargachew
Mihret, Adane
Abebe, Markos
Wassie, Liya
Gelaw, Baye
Sorsa, Abebe
Merid, Yared
Muchie, Yilkal
Teklemariam, Zelalem
Tesfaye, Bezalem
Osman, Mahlet
Jebessa, Gutema
Atinafu, Abay
Hailu, Tsegaye
Habte, Antenehe
Kenea, Dagaga
Gadisa, Anteneh
Admasu, Desalegn
Tesfaye, Emnet
Bates, Timothy A.
Bulcha, Jote Tafese
Tschopp, Rea
Tsehay, Dareskedar
Mullholand, Kim
Howe, Rawleigh
Genetu, Abebe
Tafesse, Fikadu G.
Abdissa, Alemseged
BMC INFECTIOUS DISEASES, 2022, 22 (01)
[2] High seroprevalence of anti-SARS-CoV-2 antibodies among Ethiopian healthcare workers
Tesfaye Gelanew
Berhanu Seyoum
Andargachew Mulu
Adane Mihret
Markos Abebe
Liya Wassie
Baye Gelaw
Abebe Sorsa
Yared Merid
Yilkal Muchie
Zelalem Teklemariam
Bezalem Tesfaye
Mahlet Osman
Gutema Jebessa
Abay Atinafu
Tsegaye Hailu
Antenehe Habte
Dagaga Kenea
Anteneh Gadisa
Desalegn Admasu
Emnet Tesfaye
Timothy A. Bates
Jote Tafese Bulcha
Rea Tschopp
Dareskedar Tsehay
Kim Mullholand
Rawleigh Howe
Abebe Genetu
Fikadu G. Tafesse
Alemseged Abdissa
BMC Infectious Diseases, 22
[3] Sero-prevalence of anti-SARS-CoV-2 antibodies among healthcare workers: A multicenter study from Egypt
El-Sokkary, Rehab H.
Daef, Enas
El-Korashi, Lobna A.
Khedr, Eman M.
Gad, Doaa
Mohamed-Hussein, Aliae
Zayed, Niveen E.
Mostafa, Ehab F.
Bahgat, Shereen M.
Hassany, Sahar M.
Amer, Marwa G.
El-Mokhtar, Mohamed A.
Elantouny, Neveen G.
Hassan, Shimaa A.
Zarzour, Amro A.
Hashem, Maiada K.
Amin, Mariam T.
Hassan, Hebatallah M.
JOURNAL OF INFECTION AND PUBLIC HEALTH, 2021, 14 (10) : 1474 - 1480
[4] Prevalence of anti-SARS-CoV-2 antibodies and associated factors in healthcare workers of a Mexican Covid-19 hospital
Herrera-Ortiz, Antonia
Ugo Rojas-Delgado, Hector
Garcia-Cisneros, Santa
Xibille-Friedmann, Daniel X.
Martinez-Barnetche, Jesus
Olamendi-Portugal, Maria
Minerva Gonzalez-Sanchez, Hilda
Angel Sanchez-Aleman, Miguel
SALUD PUBLICA DE MEXICO, 2022, 64 (04): : 348 - 356
[5] Duration of anti-SARS-CoV-2 antibodies much shorter in India
Kumar, Nishant
Bhartiya, Shibal
Singh, Tarundeep
VACCINE, 2021, 39 (06) : 886 - 888
[6] Anti-SARS-CoV-2 spike IgG antibodies prevalence: Correspondence
Murewanhema, Grant
Dzobo, Mathias
Dzinamarira, Tafadzwa
TRANSFUSION CLINIQUE ET BIOLOGIQUE, 2023, 30 (01) : 19 - 19
[7] Prevalence and incidence of anti-SARS-CoV-2 antibodies among healthcare workers in Belgian hospitals before vaccination: a prospective cohort study
Mortgat, Laure
Verdonck, Kristien
Hutse, Veronik
Thomas, Isabelle
Barbezange, Cyril
Heyndrickx, Leo
Fischer, Natalie
Vuylsteke, Bea
Kabouche, Ines
Arien, Kevin K.
Desombere, Isabelle
Duysburgh, Els
BMJ OPEN, 2021, 11 (06):
[8] Detection of Anti-SARS-CoV-2 Antibodies
Jahrsdoerfer, Bernd
Schrezenmeier, Hubert
TRANSFUSIONSMEDIZIN, 2021, 11 (03) : 182 - 187
[9] Prevalence of SARS-CoV-2 antibodies in pediatric healthcare workers
Morris, Claudia R.
Sullivan, Patrick
Mantus, Grace
Sanchez, Travis
Zlotorzynska, Maria
Hanberry, Bradley
Iyer, Srikant
Heilman, Stacy
Camacho-Gonzalez, Andres
Figueroa, Janet
Manoranjithan, Shaminy
Leake, Deborah
Mendis, Reshika
Cleeton, Rebecca
Chen, Christie
Krieger, Rachel
Bush, Patricia
Hughes, Tiffany
Little, Wendalyn K.
Suthar, Mehul S.
Wrammert, Jens
Vos, Miriam B.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2021, 105 : 474 - 481
[10] Anti-SARS-CoV-2 antibodies among vaccinated healthcare workers: Repeated cross-sectional study
Mishra, Sanjeeb Kumar
Pradhan, Subrat Kumar
Pati, Sanghamitra
Panda, Bimal Krushna
Bhattacharya, Debdutta
Sahu, Sumanta Kumar
Kshatri, Jaya Singh
JOURNAL OF FAMILY MEDICINE AND PRIMARY CARE, 2022, 11 (05) : 1883 - 1889

← 1 2 3 4 5 →